Disagreement on the standard adjuvant treatment for colon cancer;Dissens uber den Standard bei der adjuvanten Behandlung von Kolonkarzinomen

Zentralblatt fur Chirurgie

Volumn 122, Issue 4, 1997, Pages 210-221

  Lorenz, M ^a,b   Waldeyer, M ^a   Encke, A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

adjuvant immunotherapy; adjuvant regional therapy; adjuvant systemic therapy; colon cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; MONOCLONAL ANTIBODY;

CANCER SURVIVAL; COLON CANCER; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; REVIEW; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLON TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; MULTICENTER STUDIES; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030944289     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. AbdAlla EA, Blair GE, Jones RA (1995) Mechanism of synergy of levamisole and fluorouracil: induction of human leucocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 87: 489-496
2. Buroker T, Moertel C, Fleming T et al (1985) A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 3: 1624
3. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC (1988) Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571-3578
4. Current Clinical Trials Oncology™ (1996) May/June 1996, Pyros Education Group USA, Vol. 3: Nr. 3
5. Danenberg KD (1996) p53 status and thymidylate synthase (TS) expression are associated and predict for recurrence in patients with stage II colon cancer. Proc ASCO 15:215 Abstr. 501
6. Davis T, Borden E, Wolbert W (1982) Levamisole and 5-fluorouracil in metastatic colorectal carcinoma. Abstr. Proc. ASCO 1: 10
7. Dixon WJ, Longmire WP Jr, Holden WD (1971) Use of triethylenethiophosphomamide as adjuvant to the surgical treatment of gastric and colorectal cancer: Ten year follow-up. Ann Surg 173: 26-39
8. Fielding LP, Hittinger R, Grace RH, Fry JS (1992) Randomised controlled trial of adjuvant chemotherapy by portalvein perfusion after curative resection for colorectal adenocarcinoma. Lancet 340: 502-506
9. Francini G, Petrioli R et al (1994) Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106: 899-906
10. Gastrointestinal Tract Cancer Liason Office (GITCLO), H. Bleiberg (1996) EORTC, 2nd edition
11. GITSG (Gastrointestinal Tumor Study Group) (1984) Adjuvant therapy of colon cancer-results of a prospectively randomized trial. N Engl J Med 310: 737-743
12. Goldie JH, Coldman AJ (1993) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733
13. Graf W, Westlin JE. Påhlman L, Glimelius B (1994) Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovo- rin after colorectal cancer surgery: a randomized phase II placebo-controlled study Int J Dis 9: 35-39
14. Gray BN, DeZwart J, Fisher R (1987) The australian and new Zealand trial of adjuvant chemotherapy in colon cancer. In Salmon SE (Ed.) Adjuvant therapy of cancer. New York: Grune&Stratton
15. Haller DG (1996) Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer. Preliminary results of INT 0089. Vortrag Proc ASCO
16. Hermanek P Jr, Wiebelt H, Riedl S, Staimmer D, Hermanek P und die Studiengruppe Kolorektales Karzinom (SGKRK) (1994) Langzeitergebnisse der chirurgischen Therapie des Coloncarcinoms. Chirurg 65: 287-297
17. Hermanek P (1991) Data Collection for the design of adjuvant treatment protocols in colorectal carcinoma. Onkologie 14: 491-197
18. Higgins GA Jr. Amadeo JH, McElhinney (1984) Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel: a veterans administration surgical oncology group report. Cancer 53: 1-8
19. Higgins GA, Lee LE, Dwight RW (1978) The case for adjuvant 5-fluorouracil in colorectal cancer. Cancer Clin Trials 1: 35-41
20. Hoover HC Jr, Brandhorst JS, Peters LC, et al (1993) Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11: 390-399
21. Hryniuk WA, Figueredo A, Goodyear M (1987) Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14: suppl 4, 3-11
22. International multicentre pooled analysis of colon cancer trials (IMPACT) investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-944
23. Konsensus der CAO/AIO/ARO zur adjuvanten Therapie bei Kolon- und Rektumkarzinomen (1994) Zentralbl Chir 119: 282-283
24. Laurie JA, Moertel CG, Fleming TR et al (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and fluorouracil. J Clin Oncol 7: 1447-1456
25. Li MC, Ross ST (1976) Chemoprophylaxis for patients with colorectal cancer. JAMA 235: 2825-2828
26. Mansour EG, Cnaan A, Davis T (1990) Combined modality therapy following resection of colorectal carcinoma in patients with non-measurable intra-abdominal metastases. An ECOG study 3282. Abstr. Proc ASCO 412: 107
27. Mayer RJ (1996) Is there a standard adjuvant treatment for colon carcinoma? Pro! VIth EORTC-GITCCG Symposium, Abstract p. 22 u. Vortrag
28. Moertel C G, Fleming T R, MacDonald J S, Haller D G, Laune JA, Goodman P J, Ungerleider J S, Emerson W A, Tormey D C, Glick J H, Veeder M H, Mailliard J A (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 322: 352-358
29. Moertel CG, Fleming TR, Macdonal JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Click JH, Veeder MH, Mailliard JA (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326
30. Moertel CG (1993) Editorial-Vaccine adjuvant therapy for colorectal cancer: "very dramatic" or "ho-hum". J Clin Oncol 11: 395-396
31. Morales F, Bell M, McDonald GD, Cole WH (1957) the prophylactic treatment of cancer at the time of operation. Ann Surg 146: 588-595
32. National Cancer Institute (1989) The efficacy and the group C status of levamisole and 5-fluorouracil for patients with dukes C colon cancer. National Cancer Institute update. October
33. National Institute of Health-Consensus-Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1446.
34. O'Connell MJ, Erlichman C (1996) A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the north central cancer treatment group and the national cancer institute of canada clinical trials group. Vortrag Proc ASCO
35. Påhlman L: Open trials in colorectal cancer. Europ J Surg Oncol 21: 347-350
36. Piedbois P, Buyse M, Gray R, Clarke M, Wolmark N, Metzger U, Fielding LP, Gray B, Taylor I, Wereldsma J, Ryan J, Marsoni S, Gruenagel HH for the liver infusion metaanalysis project (1995) Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Asco 14 p 192, Abstr. 444
37. Porschen R (1996) Studiensitzungsprotokoll der Arbeitsgemeinschaft Gastroenterologische Onkologie (24.06.96) zur adjuvanten Chemotherapie des Kolonkarzinoms
38. Reynolds T (1995) Dutch trial casts doubt on colorectal adjuvant therapy. J Natl Cancer Inst 87: 476-479
39. Riethmüller G, Schneider-Gädicke E, Schlimok G (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343: 1177-1183
40. Riethmüller G (1996) Long-term follow-up of the randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Vortrag Proc ASCO
41. Ryan J, Heiden P, Crowley J, Bloch R (1988) Adjuvant portal vein infusion for colorectal cancer: a 3-arm randomized trial. Proc ASCO 7: 362
42. Sahmoud T, Rougier P, Nitti D, Doci R, de Waele B, Nakajima T, Rauschecker H, Curran D, Sakamoto J, Labianca R, Pector JC, Marsoni S, Torri V, Bleiberg H, Couvreur ML, Wils J (1996) An EORTC-GIVIO Inter-group phase III trial of adjuvant portal vein infusion of 5-FU and heparin (PVI) in colorectal cancer. VIth EORTC-GITCCG Symposium. Abstract p 84 u. Vortrag
43. Scheithauer W (1996) Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Vortrag Proc ASCO
44. Stevenson HC, Green I, Hamilton JM (1991) Levamisole. known effects on the immune system, clinical results and future applications to the treatment of cancer. J Clin Ocol: 9: 2052-2066
45. Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE ( 1985) Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98: 414-421
46. Swiss Group for Clinical Cancer Research (SAKK) (1995) Long term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345: 349-353
47. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C (1985) A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 72: 359-263
48. The AXIS Colorectal Cancer Trial (1994) Randomization of over 2000 patients. Br J Surg 72: 1672
49. Vermorken JB, Claessen AME, Gall HE, Ezinga RD, van Tinteren H, Meijer S, Steffelaar H, Butzelaar RMJM, Brakenhoff JAC, van Bochove A, Scheper RJ, Meijer CLJM, Hanna MG, Pinedo HM (1996) Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with dukes B2, B3 or C colon cancer. Abstr Proc ASCO
50. Wassner A, Heidemann E (1996) Levamisole and 5-Fluorouracil as an adjuvant therapy for patients after curative section of colon carcinoma Dukes' stage C (TNM III): more disadvantages than advantages. Onkologie 19: 140-145
51. Weber W, Maibach R, Laffer U, Metzger U, Egeli R, Lorenz M, Aeberhard P, Dupont-Lampert V, Nöthiger F, Rüedi Th, Castiglione M (1995) Early hematological toxicity of adjuvant perioperative intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. Schweizer Krebs Bull Nr. 2: 39-42
52. Wereldsma J C, Bruggink E D, Meijer W S, Roukema J A, van Putten W L (1990) Adjuvant portal liver infusion on colorectal cancer with 5-FU/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I), Cancer 65: 425-432.
53. Windle R, Bell PRF, Shaw D (1987) Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 74: 569-572
54. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N, Jochimsen P, other NSABP Investigators (1988) Postoperative adjuvant chemotherapy or BCG for Colon Cancer: Results from NSABP protocol C-01. J Natl Cancer Inst 80: 3-36
55. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, DeFusco P, Jochimsen P (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 11: 1879-1887
56. Wolmark N, Rockette H, Wickerham DL, Fisher B, Redmond C, Fisher ER, Potvin M, Davies RJ, Jones J, Robidoux A, Wexler M, Gordon P, Cruz AB Jr, Horsley S, Nims TA, Thirlwell M, Phillips WA, Prager D, Stern SS, Lerner HJ, Frazier TG (1990) Adjuvant therapy of dukes'A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion. Preliminary results of the national surgical adjuvant breast and bowel project protocol C-02. J Clin Oncol 8: 1466-1475
57. Wolmark N (1996) The relative efficacy of 5-FU plus leuvovorin and 5-FU/levamisole and 5-FU/leucovorin/ levamisole in patients with dukes B and C colon carcinoma. Vortrag Proc ASCO
58. Zoetmulder F, Taal BG et al (1996) Interim analysis of the netherlands adjuvant colorectal cancer study. Eur J Cancer in press